Oleclumab

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameOleclumab
Drug Alias NameAnti-CD73 monoclonal antibody (MedImmune)Anti-CD73 MAb (MedImmune)MEDI-9447
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of Action5'-nucleotidase inhibitorsImmunomodulators
Targets5'-nucleotidase
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[30] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteJules Bordet InstituteAstrazeneca Plc +[10] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[18] 
Inactive IndicationsSquamous Cell Carcinoma of Head and NeckCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A